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Background People aged 85 years and older are the
fastest growing age group worldwide. This study
assessed respiratory health, prevalence of respiratory
disease and use of spirometry in respiratory diagnosis in
a population-based cohort of 85 year olds to better
understand respiratory health and disease in this sector
of society.
Methods A single year birth-cohort of 85 year olds
participated in a respiratory assessment at their home or
residential institution including self-reporting of
symptoms and measurement of spirometry. General
practice medical records were reviewed for respiratory
diagnoses and treatments.
Findings In the 845 participants, a substantial burden
of respiratory disease was seen with a prevalence of
COPD in medical records of 16.6% (n=140). A large
proportion of the cohort had environmental exposures
through past or current smoking (64.2%, n=539) and
occupational risk factors (33.6%, n=269). Spirometry
meeting reliability criteria was performed in 87%
(n=737) of participants. In the subgroup with a
diagnosis of COPD (n=123), only 75.6% (n=93)
satisfied Global Initiative in Obstructive Lung Disease
(GOLD) criteria for airflow obstruction, and in a healthy
subgroup without respiratory symptoms or diagnoses
(n=151), 44.4% (n=67) reached GOLD criteria for
airflow obstruction and 43.3% (n=29) National Institute
of Health and Care Excellence criteria for at least
moderate COPD.
Interpretation Spirometry can be successfully
performed in the very old, aged 85 years, and may help
identify respiratory diseases such as COPD. However
interpretation in this age group using current definitions
of COPD based on spirometry indices may be difficult
and lead to overdiagnosis in a healthy group with
transient symptoms.
INTRODUCTION
The very old, aged 85 years and older, are now the
most rapidly expanding age sector of most popula-
tions worldwide.1 Data from the 2011 England and
Wales Census showed a doubling of the over 85
years age group between 1985 and 2010, from
nearly 0.7 million to over 1.4 million,2 and
numbers are projected to double again between
2010 and 2030.3 This age group frequently uses
healthcare resource in primary and secondary
care,4 and therefore understanding their health
status and burden of disease is important for train-
ing of health professionals and for organisation of
healthcare provision.
Symptoms relating to the respiratory system, in
particular dyspnoea, are common in those 85 years
and older with a prevalence of over 40%,5 and are
frequently a reason for older people to seek health-
care. Although it is recognised that many chronic
respiratory diseases increase in prevalence and
severity with age, it is also clear that dyspnoea is
non-specific and may be associated with non-
pulmonary morbidities.6 In the very old, assess-
ment of respiratory health is further complicated
by the physiological changes that occur as part of
‘normal’ or ‘healthy’ ageing, such as loss of lung
elasticity and reduced thoracic cage movement,
which will have an effect on objective measures of
lung function.7
Current national and international guidelines on
the management of COPD have obstructive spirom-
etry (FEV1/FVC ratio <0.7) as a key diagnostic test
directing physicians towards the use of specific
Key messages
What is the key question?
▸ What is the burden of respiratory disease and
utility of spirometry in aiding assessment of
respiratory health and diagnosis of respiratory
disease in community-living 85 year olds in the
UK?
What is the bottom line?
▸ The study reveals a substantial burden of
respiratory disease and symptoms in 85 year
olds but also considerable discordance between
physician-diagnosed COPD and confirmatory
spirometry evidence in the very old that have
important implications for clinical practice.
Why read on?
▸ This study represents the largest and most
detailed assessment to date of respiratory
health status and challenges of using
spirometry criteria in respiratory diagnosis in
the very old, aged 85 years and over, which are
now the fastest growing sector of the
population.
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respiratory medications.8 9 However, the accuracy of lung func-
tion criteria for the diagnosis of airflow obstruction or restrictive
lung disease in very old people has been questioned due to the
intrapulmonary and extrapulmonary physiological changes that
occur in this age group as part of normal ageing.10 This may
cause misdiagnosis and inappropriate use of medications in this
population. Moreover, a previous study in a population with a
mean age of 73 years suggested that COPD may be either over-
diagnosed or underdiagnosed depending on the approach taken
to defining abnormal lung function.11
This study aimed to address the lack of knowledge about
respiratory health, prevalence of lung disease and objective mea-
sures of lung function in the very old using baseline data from
the Newcastle 85+ Study,4 12 a large population-based cohort
of 85 year olds. Specifically the study aimed to: assess the extent
of common respiratory symptoms and the prevalence of
physician-diagnosed lung disease, particularly COPD; and to
assess the accuracy of COPD diagnosis based on lung function
measurements, respiratory symptoms and identification of risk
factors, and the degree to which respiratory medication was
appropriately prescribed. Finally, in a healthy reference group
(HRG), the study aimed to evaluate the applicability of three
standard methods of interpreting lung function measurements
as normal or abnormal to disentangle the effects of lung disease
and ‘normal’ or ‘healthy’ ageing on measured lung function.
METHODS
Full details of the Newcastle 85+ Study methodology have been
reported.12 In brief, members of the 1921 birth cohort living in
Newcastle upon Tyne or North Tyneside (North-East England)
were recruited around their 85th birthday over a 17 -
month-period spanning 2006 and 2007. Participants included
people living at home or in institutional care and regardless of
their current health status. More detailed methods are available
as online supplementary materials.
Existing diagnoses of respiratory disease, respiratory
symptoms, respiratory medications and environmental risk
factors
Current and past respiratory diagnoses were identified from a
general practice records review (GPRR) using a predetermined
checklist of chronic respiratory diseases. Data on use, but not
doses, of respiratory medications were also obtained from
GPRR. Data on symptoms of breathlessness, cough, wheeze and
sputum production were obtained by a structured questionnaire
administered as part of a domiciliary multidimensional health
assessment (MDHA) conducted by a research nurse in the parti-
cipant’s home or institution. Specifically, participants were asked
whether shortness of breath limited their day-to-day activities
and responses were then used to assign an Medical Research
Council (MRC) dyspnoea score.8 Participants were asked about
any relevant environmental exposure in their occupation or at
home, specifically detailed smoking history and relevant occupa-
tional history (including exposure to heavy industry generally as
well as the chemical industry, asbestos and coal mining). Two
measures of disease burden were used: a disease count
(maximum 18 diseases) previously determined in the cohort;
and a non-respiratory disease count excluding COPD and other
respiratory disease (maximum 16 diseases).4 Further details of
the individual respiratory diagnoses, medications and chronic
non-respiratory diseases included in the disease count are pro-
vided (see online supplementary methods).
Lung function measurements
Spirometry and peak flow measurements were performed at the
participant’s place of residence by a trained research nurse using
MicroLab Spirometer and Spida V.5 software (Micro Medical,
Rochester, UK). The aim was to obtain three technically satisfac-
tory maximal effort ‘blows’ to generate reproducible FEV1, FVC
and peak expiratory flow measurement (PEF); blows were
repeated until this was achieved or maximum effort reached.
Blows were assessed for technical adequacy using in-built Spida
algorithms. All spirometry curves were assessed independently by
a respiratory clinical physiologist and those able to produce at least
two adequate blows were included in the analysis. If the necessary
quality was lacking they were excluded from analysis. Demispan
was measured as a surrogate for height13 (calculated using stand-
ard equations) and height used with age and gender to calculate
predicted values for FEV1, FVC and peak flow using equations in
the UK Department of Health guide.9 Spirometry was classified
(see online supplementary table S2) as normal, obstructive or
restrictive based on the FEV1/FVC ratio of 0.7 and the percentage
of predicted values for FEV1 and FVC, with obstructive spirom-
etry further classified as mild, moderate or severe based on Global
Initiative in Obstructive Lung Disease (GOLD) criteria.10 In add-
ition, we reanalysed the data using criteria presented by the Global
Lung Function Initiative (GLI)14 which provides alternative predic-
tion model equations validated for ages 3 years to 95 years (see
online supplementary tables S3–S5).
Healthy reference group
To establish the distribution of normal lung function in
people aged 85 years, we identified a HRG of participants
with no respiratory symptoms, no respiratory diagnoses, no
current use of respiratory medications and no non-respiratory
diagnosis which might influence lung function (eg, Parkinson’s
disease, kyphoscoliosis, heart failure, ankylosing spondylitis) in
their GPRR. Those with a BMI >30 were also excluded from
HRG. Lung function in the HRG was compared against
equation derived15 predicted values based on gender and
height by three accepted methods: percentage predicted
value; lower limit of normal (LLN) using American Thoracic
Society/European Respiratory Society (ATS/ERS) criteria;16
and Z scores.
Statistical methods
Gender differences in respiratory symptoms, diagnoses, environ-
mental exposures and medications were examined using χ2 and
Mann-Whitney U tests. Gender differences in lung function
were investigated in the whole sample, COPD group and the
HRG using Mann-Whitney U test for continuous measures, χ2
and Fisher’s exact tests for categorised measures and
Kruskal-Wallis test for ordered categorised measures. The rela-
tionship between FEV1 and PEF scores was assessed using
Pearson’s correlation coefficients. Sensitivity analyses were
carried out to examine differences between those included and
excluded from analysis due to lack of spirometry measures and
those with and without an MRC dyspnoea score. All analyses
were conducted using Stata V.12.0 (StataCorp; College Station,
Texas, USA).
RESULTS
Sociodemographic, non-respiratory health characteristics
and environmental exposures of the study population
Details of the Newcastle 85+ Study population have been
reported previously, and the study population was broadly
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sociodemographically representative of the local population,
and of England and Wales, including the proportion in institu-
tional care.4 Data from MDHA and GPRR was available for
845 participants, 58.2% (845/1453) of those eligible (figure 1);
their mean (SD) age was 85.5 (0.4) years, 62.3% (526/845)
were female and 99.6% (839/845) were of white ethnic group
(table 1). Three-quarters were living in standard housing, 12.8%
(108/845) in warden-supported accommodation and 10.2% (86/
845) in institutional care. The median (IQR) chronic disease
count was 5(3–6) with no significant gender difference
Figure 1 Flow chart illustrating how the total cohort of Newcastle 85+ Study participants was subdivided in the respiratory study sample,
demonstrating why different numbers of participants are included in the analyses. The derivation of the study groups are shown in the flow chart;
note that for some variables the number of participants included is less than 845 due to missing data, the reasons for which are detailed. The basis
for the healthy reference group (HRG) was the 845 participants who had multidimensional health assessment (MDHA) and general practice records
review (GPRR) conducted. Of these, 786 (93.0%) had spirometry performed of whom 772 performed it adequately; a further 35 participants with
missing demispan were removed (unable to calculate predicted blows), resulting in 737. Participants with at least one respiratory condition, those
with respiratory symptoms and those on respiratory medication were excluded which reduced the group size to 170. Other conditions which have an
effect on spirometry values were also taken into account leading to exclusion of a further 19 participants. The remaining 151 (17.9% of 845)
participants formed the HRG.
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(p=0.074). Although the 845 participants were a non-random
sample of the eligible population, data from an additional 188
participants (18%) who opted for GPRR only showed no differ-
ence in respiratory diagnoses compared with those who partici-
pated fully.
Almost three quarters (74.4%, 235/316) of men and over half
of women (58.0%, 304/524) had smoked in their lifetime,
although very few (men: 4.4%, 14/316; women: 6.5%, 34/524)
were current smokers. A significant proportion of men and
women had occupational exposures which may have influenced
respiratory health, with much higher prevalence in men (heavy
industry: 41.2%, 126/306; coal mining: 11.4%, 35/307; chemical
industry: 11.1%, 34/306; asbestos: 28.9%, 88/305), reflecting
common historical occupations in this region of the UK (table 1).
Table 1 Sociodemographic and health characteristics of the total Newcastle 85+ cohort (n=845) and by gender
Men (n=319) Women (n=526) Overall cohort (n=845) p Value*
Ethnicity % (N)
White 99.4 (316) 99.8 (523) 99.6 (839) 0.272†
Living arrangements % (N)
Standard housing 83.4 (266) 73.2 (385) 77.0 (651) 0.002†
Sheltered housing 10.3 (33) 14.3 (75) 12.8 (108)
Institutional care 6.3 (20) 12.6 (66) 10.2 (86)
Smoking % (N)
Never 25.6 (81) 42.0 (220) 35.8 (301) <0.001†
Former 69.9 (221) 51.5 (270) 58.5 (491)
Current 4.4 (14) 6.5 (34) 5.7 (48)
Occupational exposures % (N)
Heavy industry 41.2 (126) 16.6 (83) 25.9 (209) <0.001†
Coal mining 11.4 (35) 0.0 (0) 4.3 (35) <0.001‡
Chemical industry 11.1 (34) 4.0 (20) 6.7 (54) <0.001†
Asbestos exposure 28.9 (88) 1.6 (8) 12.0 (96) <0.001†
Respiratory symptoms % (N)
Cough 28.3 (88) 25.8 (129) 26.7 (217) 0.425†
Wheeze 25.0 (78) 20.2 (101) 22.0 (179) 0.109†
Sputum production 40.7 (127) 28.0 (140) 32.9 (267) <0.001
MRC dyspnoea score % (N)
1 50.2 (123) 40.5 (143) 44.5 (266) 0.048§
2 11.4 (28) 19.0 (67) 15.9 (95)
3 20.4 (50) 17.6 (62) 18.7 (112)
4 15.1 (37) 17.0 (60) 16.2 (97)
5 2.9 (7) 6.0 (21) 4.7 (28)
Respiratory diagnoses % (N)
COPD 17.9 (57) 15.8 (83) 16.6 (140) 0.429†
Asthma 6.9 (22) 12.7 (67) 10.5 (89) 0.007†
Bronchiectasis 2.5 (8) 1.5 (8) 1.9 (16) 0.308†
Pulmonary fibrosis 0.0 (0) 0.2 (1) 0.1 (1) 1.000‡
Asbestosis 1.6 (5) 0.0 (0) 0.6 (5) 0.008‡
Pneumoconiosis 1.3 (4) 0.0 (0) 0.5 (4) 0.020‡
TB 4.4 (14) 4.9 (26) 4.7 (40) 0.713†
Respiratory medications
Inhaled short-acting β-2 adrenoreceptor agonists 9.1 (29) 11.4 (60) 10.5 (89) 0.288†
Inhaled muscarinic antagonists 3.8 (12) 3.8 (20) 3.8 (32) 0.976†
Oral theophylline 0.3 (1) 0.5 (3) 0.5 (4) 0.598‡
Combination short-acting bronchodilators 0.6 (2) 0.0 (0) 0.2 (2) 0.142‡
Inhaled corticosteroids 5.3 (17) 7.8 (41) 6.9 (58) 0.169†
Combination inhaled Corticosteroids and long-acting β-2 adrenoreceptor agonists 1.9 (6) 2.1 (11) 2.0 (17) 0.833†
Oral leukotriene receptor antagonists 0.0 (0) 0.4 (2) 0.2 (2) 0.529‡
Oral mucolytics 0.6 (2) 0.2 (1) 0.4 (3) 0.560‡
At least one respiratory medication
% (N) 12.2 (39) 14.5 (76) 13.6 (115) 0.361†
Disease count
median (IQR) 4 (3–6) 5 (4–6) 5 (3–6) 0.074§
Comorbid disease count
median (IQR) 4 (3–6) 5 (4–6) 5 (3–6) 0.047§




Denominators vary due to missing values.
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Respiratory diagnoses, symptomatology and medication use
The most common physician-diagnosed respiratory condition
was COPD with a prevalence of 16.6% (140/845) and no sig-
nificant gender difference (p=0.43) (table 1). A diagnosis of
asthma had been made in 10.5% (89/845) with a predominance
in women (men: 6.9%; women: 12.7%; p=0.007). Other
respiratory diagnoses were rare.
Chronic cough was self-reported in 26.7% (217/812) and
wheeze in 22.0% (179/812) of participants. Regular sputum
production was more common in men (men: 40.7%, 127/312;
women: 28.0%, 140/500; p<0.001). An MRC dyspnoea score
was assigned in 598 (70.8%) participants since in the other par-
ticipants their activity could be limited by other non-respiratory
conditions. Half (123/245) of the men and 40.5% (143/353) of
the women allocated an MRC dyspnoea score had no limita-
tions to their daily activities due to breathlessness.
The most frequently prescribed respiratory medications were
inhaled short-acting β-2 adrenoreceptor agonists (10.5%, 89/
845 of participants) followed by inhaled corticosteroids (6.9%,
58/845) (table 1). Only 2.0% (17/845) were taking a
combination inhaler containing corticosteroid and a long-acting
β-2 adrenoreceptor agonist. The use of other respiratory medi-
cations was unusual (table 1).
Lung function measurements
Spirometry was performed by 786 (93.0%) participants
(figure 1), most of whom (98.2%, 772/786) provided at least
two adequate blows conforming to ATS/ERS guidelines.
Demispan was available for 737 participants with adequate
expiratory effort and consistency allowing calculation of pre-
dicted spirometry values, with these 737 forming the spirometry
group (table 2). Comparison of the spirometry group (n=737)
with those excluded due to missing/inadequate spirometry and/
or missing demispan (n=108) showed those excluded were more
likely to be female, living in an institution and with previous
exposure to the chemical industry, but not significantly different
in smoking history; respiratory symptoms, diagnoses or medica-
tions; or dyspnoea scores (see online supplementary table S1).
Of the whole spirometry group, 31.2% (230/737) had a
normal FEV1/FVC ratio and 15.2% (112/737) had a restrictive
Table 2 Results of spirometry in the cohort completing spirometry with adequate reproducible blows and demispan available for calculation of
predicted blows (n=737)
Men (n=293) Women (n=444) All (n=737) p Value*
Actual spirometry median (IQR)
FEV1 (l/s) 1.8 (1.4–2.2) 1.2 (1.0–1.5) 1.4 (1.1–1.8) <0.001†
FVC (l/s) 2.7 (2.2–3.2) 1.8 (1.4–2.1) 2.0 (1.6–2.6) <0.001†
FEV1/FVC 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.006†
PEF (L/m) 441 (323–604) 283 (196–362) 328 (233–450) <0.001†
% predicted median (IQR)
FEV1 78.8 (62.4–94.3) 83.4 (68.1–98.8) 81.5 (65.6–97.1) 0.008†
FVC 83.4 (70.3–99.6) 96.6 (79.1–113.7) 90.8 (74.1–108.4) <0.001†
Spirometry % (N)
Normal 28.0 (82) 33.3 (148) 31.2 (230) 0.108‡
Restrictive 13.7 (40) 16.2 (72) 15.2 (112)
Obstructive 58.4 (171) 50.5 (224) 53.6 (395)
Grading of obstructive spirometry§ % (N)
Mild 35.7 (61) 43.3 (97) 40.0 (158) 0.059¶
Moderate 46.8 (80) 45.1 (101) 45.8 (181)
Severe 14.6 (25) 9.8 (22) 11.9 (47)
Very severe 2.9 (5) 1.8 (4) 2.3 (9)
FEV1 % (N)
Below LLN 25.9 (76) 13.3 (59) 18.3 (135) <0.001**
Normal range 73.7 (216) 85.6 (380) 80.9 (596)
Above ULN 0.3 (1) 1.1 (5) 0.8 (6)
FEV1 Z-score
median (IQR) 1.0 (0.2–1.7) 0.6 (0.0–1.2) 0.8 (0.1–1.4) <0.001†
FVC % (N)
Below LLN 21.2 (62) 9.2 (41) 14.0 (103) <0.001‡
Normal range 77.1 (226) 86.3 (383) 82.6 (609)
Above ULN 1.7 (5) 4.5 (20) 3.4 (25)
FVC Z-score
median (IQR) 0.9 (0.0–1.5) 0.1 (−0.6–0.9) 0.4 (−0.4–1.2) <0.001†
Oxygen saturation
median (IQR) 97 (96–98) 97 (96–98) 97 (96–98) 0.513†
*Comparison of men and women.
†Mann–Whitney U test.
‡χ2 test.
§This is based on the 395 participant subsample with obstructive spirometry.
¶Kruskal–Wallis test.
**Fisher’s exact test.
LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.
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Figure 2 Distribution curves of FEV1 and FVC in all participants in spirometry cohort (all, men and women) measured (blue) and predicted (green).
Figure 3 Scatter plots of spirometry and peak expiratory flow in all participants in spirometry cohort.
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pattern. Obstructive spirometry was the most common finding
(men: 58.4%, 171/293; women: 50.5%, 224/444) but with no
gender difference in the spread of severity (table 2). Measured
values of FEV1, FVC and PEF in the spirometry group were
normally distributed but with a much wider distribution range
than that of the predicted values (figure 2). Scatter plots of the
measured FEV1 and FVC against the predicted values showed
more participants with measured values below the predicted
values than above suggesting a downward shift in the population
as a whole (figure 3). The spread of FEV1 measurements around
the predicted values was much wider in men than women.
Prevalence and accuracy of physician-diagnosed COPD
Of the spirometry group, 16.7% (123/737) had physician-
diagnosed COPD (COPD group) of whom 57.7% (71/123)
were female and 23.8% (29/123) reported being ‘never
smokers’ (table 3). More than half of the ‘never smokers’ with a
COPD diagnosis had no occupational exposures either.
In the COPD group, only 45.5% (56/123) were taking short-
acting inhaled β-2 adrenoreceptor agonist bronchodilator
therapy, 20.3% (25/123) were taking inhaled long-acting mus-
carinic antagonists, 41.5% (51/123) were on inhaled corticoster-
oids either as monotherapy (36/51) or in combination with a
Table 3 Descriptive characteristics of subset with physician-diagnosed COPD in general practitioner records
Men (n=52) Women (n=71) All (n=123) p Value*
Smoking % (N)
Never 21.2 (11) 25.7 (18) 23.8 (29) 0.637†
Former 67.3 (35) 67.1 (47) 67.2 (82)
Current 11.5 (6) 7.1 (5) 9.0 (11)
Occupational exposure % (N)
Heavy industry 49.0 (25) 19.7 (14) 32.0 (39) 0.001†
Coal mining 17.7 (9) 0.0 (0) 7.4 (9) <0.001‡
Chemical 13.7 (7) 2.8 (2) 7.4 (9) 0.034‡
Asbestos 33.3 (17) 7.1 (5) 18.2 (22) <0.001†
Non-smokers with no occupational exposures % (N) 3.9 (2) 18.3 (13) 12.2 (15) 0.023†
Respiratory symptoms % (N)
Cough 46.2 (24) 53.5 (38) 50.4 (62) 0.419†
Wheeze 53.9 (28) 56.3 (40) 55.3 (68) 0.784†
Sputum production 63.5 (33) 54.3 (38) 58.2 (71) 0.310†
MRC dyspnoea score % (N)
1 26.8 (11) 12.5 (7) 18.6 (18) 0.035§
2 9.8 (4) 16.1 (9) 13.4 (13)
3 34.2 (14) 19.6 (11) 25.8 (25)
4 22.0 (9) 33.9 (19) 28.9 (28)
5 7.3 (3) 17.9 (10) 13.4 (13)
Comorbid respiratory diagnoses % (N)
Asthma 25.0 (13) 49.3 (35) 39.0 (48) 0.006†
Bronchiectasis 7.7 (4) 2.8 (2) 4.9 (6) 0.240‡
Asbestosis 7.7 (4) 0.0 (0) 3.3 (4) 0.030‡
Pulmonary fibrosis 0.0 (0) 0.0 (0) 0.0 (0) –
Pneumoconiosis 3.9 (2) 0.0 (0) 1.6 (2) 0.177‡
TB 5.8 (3) 9.9 (7) 8.1 (10) 0.516‡
Medications % (N)
Inhaled short-acting β-2 adrenoreceptor agonists 36.5 (19) 52.1 (37) 45.5 (56) 0.087†
Inhaled muscarinic antagonists 17.3 (9) 22.5 (16) 20.3 (25) 0.477†
Oral theophylline 1.9 (1) 4.2 (3) 3.3 (4) 0.637‡
Combination short-acting bronchodilators 1.9 (1) 0.0 (0) 0.8 (1) 0.423‡
Inhaled corticosteroids 17.3 (9) 38.0 (27) 29.3 (36) 0.013†
Combination inhaled corticosteroids and long-acting β-2 adrenoreceptor agonists 11.5 (6) 12.7 (9) 12.2 (15) 0.849†
Oral leukotriene receptor antagonists 0.0 (0) 1.4 (1) 0.8 (1) 1.000‡
Oral mucolytics 1.9 (1) 1.4 (1) 1.6 (2) 1.000‡
Oral glucocorticoid therapy 5.8 (3) 4.2 (3) 4.9 (6) 0.697‡
At least 1 respiratory medication % (N) 46.2 (24) 66.2 (47) 57.7 (71) 0.026†
Disease count
median (IQR) 5 (4–7) 6 (5–7) 6 (4–7) 0.156§
Non-respiratory disease count
median (IQR) 5 (4–6) 6 (5–7) 6 (4–7) 0.064§




Denominators vary due to missing values.
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long-acting β-agonist (15/51). There was minimal use of theo-
phylline preparations, oral mucolytics or oral leukotriene recep-
tor antagonists and none of the COPD group used home
oxygen (table 3). The proportion of the COPD group that were
on at least one respiratory medication differed significantly
between men and women (men: 46.2%, 24/52; women: 66.2%,
47/71; p=0.026), although a sizeable proportion (42.3%, 52/
123) of those with a COPD diagnosis were not on any (table 3).
There was a significant overlap in the diagnoses of asthma and
COPD with 61% (48/78) of those with an asthma diagnosis also
being diagnosed with COPD.
Respiratory symptoms were common but not universal in the
COPD group with 50.4% (62/123) reporting cough and 58.2%
(71/123) sputum production. Nevertheless 26.8% (11/52) of
men and 12.5% (7/71) of women with a COPD diagnosis had
only minimal breathlessness (MRC dyspnoea score=1).
Only 75.6% (93/123) of the COPD group had obstructive
spirometry by GOLD criteria (table 4). There was no gender dif-
ference in severity of airflow obstruction (based on % predicted
FEV1) and only 63.4% (78/123) of the COPD group fulfilled
the UK National Institute of Health and Care Excellence
(NICE) guidelines spirometry definition of moderate, severe or
very severe disease (table 4). Furthermore, only 63.4% (78/123)
of the COPD group fulfilled the UK NICE guidelines spirometry
definition of moderate, severe or very severe disease. When
FEV1 was classified by the LLN approach, 48.1% (25/52) of
men and 33.8% (24/71) of women from the COPD group fell
below the LLN with all other participants falling between the
LLN and upper limit of normal, suggesting that a substantial
proportion (60.2%, 74/123) of those with physician-diagnosed
COPD had an FEV1 in the normal range and/or no airflow
obstruction on spirometry measurement. When applying the
GLI prediction models to the COPD group, 48.1% (25/52) men
and 50.7% (36/71) women satisfied criteria for airflow obstruc-
tion (see online supplementary table S4). The degree of agree-
ment between physician-diagnosed COPD and spirometric
evidence of airflow obstruction using either GOLD or GLI cri-
teria is poor when assessed by the McNemar test (see online
supplementary table S6).
Assessment of lung function in an HRG
Figure 1 shows the derivation of the HRG which comprised
20.5% (151/737) of the spirometry cohort (table 5). The distri-
bution of measured and predicted FEV1, FVC and PEF in this
Table 4 Results of spirometry in the subgroup with physician-diagnosed COPD (n=123)
Men (n=52) Women (n=71) All (n=123) p Value*
Actual median (IQR)
FEV1 1.4 (1.1–1.8) 1.0 (0.7–1.1) 1.1 (0.8–1.4) <0.001†
FVC 2.4 (2.0–3.1) 1.6 (1.3–1.9) 1.9 (1.5–2.3) <0.001†
FEV1/FVC 0.6 (0.5–0.7) 0.6 (0.5–0.7) 0.6 (0.5–0.7) 0.591†
PEF 382.5 (243–519) 218 (144–290) 259 (191–380) <0.001†
%predicted median (IQR)
FEV1 63.5 (50.9–73.4) 64.2 (51.7–79.9) 64.2 (51.3–76.4) 0.609†
FVC 77.4 (64.2–94.1) 87.6 (70.4–101.0) 82.8 (68.2–99.8) 0.040†
Spirometry %(N)
Normal 7.7 (4) 8.5 (6) 8.1 (10) 0.959‡
Restrictive 15.4 (8) 16.9 (12) 16.3 (20)
Obstructive 76.9 (40) 74.7 (53) 75.6 (93)
Obstructive spirometry§ %(N)
Mild 10.0 (4) 20.8 (11) 16.1 (15) 0.190¶
Moderate 60.0 (24) 56.6 (30) 58.1 (54)
Severe 27.5 (11) 20.8 (11) 23.7 (22)
Very severe 2.5 (1) 1.9 (1) 2.2 (2)
FEV1 %(N)
Below LLN 48.1 (25) 33.8 (24) 39.8 (49) 0.137**
Normal range 51.9 (27) 66.2 (47) 60.2 (74)
Above ULN 0.0 (0) 0.0 (0) 0.0 (0)
FEV1 Z-score
median (IQR) 1.6 (1.2–2.2) 1.3 (0.7–2.0) 1.5 (0.9–2.0) 0.039†
FVC %(N)
Below LLN 30.8 (16) 14.1 (10) 21.1 (26) 0.043**
Normal range 69.2 (36) 84.5 (60) 78.1 (96)
Above ULN 0.0 (0) 1.4 (1) 0.8 (1)
FVC Z-score
median (IQR) 1.1 (0.3–1.8) 0.6 (0.0–1.2) 0.8 (0.0–1.6) 0.008†
Oxygen saturation
median (IQR) 97 (96–98) 97 (95–98) 97 (95–98) 0.521†
*Comparison of men and women.
†Mann–Whitney U test.
‡χ2 test.
§This is based on the 93 participant subsample with obstructive spirometry.
¶Kruskal–Wallis test.
**Fisher’s exact test.
LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.
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group, by gender, are shown in figure 4 and table 5, with scatter
plots of measured versus predicted FEV1 and FVC by gender in
figure 5.
Approximately half of the HRG (men: 47.4%, 27/57;
women: 42.6%, 40/94) had a spirometry definition of airflow
obstruction by GOLD criteria (table 5) yet did not fulfil the
requirements for a diagnosis of COPD through lack of symp-
toms. Interestingly 19.2% (29/151) fulfilled a spirometry defin-
ition of at least moderate COPD using NICE criteria
(obstructive spirometry and an FEV1 <80% predicted). The
measured best PEF median (IQR) for this group was 367 (263–
515) L/min, significantly higher in men (515 (340–647) L/min)
than in women (329.5 (243–417) L/min) (p<0.001), and highly
correlated with FEV1 (figure 5). When applying the GLI criteria
to HRG only 17.5% (10/57) men and 16% (15/94) women (see
online supplementary table 5) fulfilled criteria for airflow
obstruction suggesting that GLI offered superiority to GOLD in
spirometry interpretation in this age group.
The measured spirometry values in HRG were compared
with equation-derived15 predicted values based on gender and
height using three different accepted approaches: percentage
predicted value, LLN and Z scores (table 5). The median (IQR)
percentage predicted value FEV1 in HRG was 90.1% (67.6–
103.8%) in men and 93.8% (78.6–106.0%) in women. The
measured FEV1 fell below LLN in 11.3% (17/151) of partici-
pants with a large gender difference (men: 21.1%, 12/57;
women: 5.3%, 5/94; p=0.008). A significant gender difference
was also found for the proportion of measured FVC falling
below LLN with observed gender difference in the median
Z-scores (table 5).
DISCUSSION
This study presents the first evaluation of respiratory symptom-
atology, respiratory disease prevalence and objectively measured
lung function in a large UK population-based single-year birth
cohort of 85 year olds. It provides insight into the burden of
respiratory disease and degree of respiratory impairment in
very old people in an urban setting, and illustrates a popula-
tion with substantial environmental exposures and smoking
history, even in women. Furthermore, despite the higher rate
of cognitive impairment with age, 93% of our cohort per-
formed spirometry and of these 98% did so successfully which
challenges reluctance to use spirometry in the very old and
Table 5 Results of spirometry in healthy reference group of participants (n=151)
Men (n=57) Women (n=94) All (n=151) p Value*
Actual median (IQR)
FEV1 2.0 (1.7–2.4) 1.4 (1.2–1.6) 1.5 (1.2–2.0) <0.001†
FVC 2.9 (2.4–3.5) 1.9 (1.6–2.2) 2.1 (1.8–2.8) <0.001†
FEV1/FVC 0.7 (0.6–0.8) 0.7 (0.7–0.8) 0.7 (0.6–0.8) 0.244†
PEF 515 (340–647) 329.5 (243–417) 367 (263–515) <0.001†
%predicted median (IQR)
FEV1 90.1 (67.6–103.8) 93.8 (78.6–106.0) 91.6 (76.0–106.0) 0.154†
FVC 92.3 (72.0–107.7) 101.2 (85.2–121.7) 97.5 (80.6–115.2) 0.006†
Spirometry %(N)
Normal 38.6 (22) 44.7 (42) 42.4 (64) 0.764‡
Restrictive 14.0 (98) 12.8 (12) 13.3 (20)
Obstructive 47.4 (27) 42.6 (40) 44.4 (67)
Obstructive spirometry§ %(N)
Mild 48.2 (13) 62.5 (25) 56.7 (38) 0.137¶
Moderate 33.3 (9) 32.5 (13) 32.8 (22)
Severe 11.1 (3) 5.0 (2) 7.5 (5)
Very severe 7.4 (2) 0.0 (0) 3.0 (2)
FEV1 %(N)
Below LLN 21.1 (12) 5.3 (5) 11.3 (17) 0.008**
Normal range 77.2 (44) 93.6 (88) 87.4 (132)
Above ULN 1.8 (1) 1.1 (1) 1.3 (2)
FEV1 Z-score
median (IQR) 0.5 (−0.2–1.6) 0.3 (−0.2–0.9) 0.3 (−0.2–1.0) 0.071†
FVC %(N)
Below LLN 19.3 (11) 1.1 (1) 8.0 (12) <0.001**
Normal range 79.0 (45) 91.5 (86) 86.8 (131)
Above ULN 1.8 (1) 7.5 (7) 5.3 (8)
FVC Z-score
median (IQR) 0.4 (−0.4–1.5) −0.1 (−0.9–0.6) 0.1 (−0.7–0.9) 0.004†
Oxygen saturation
median (IQR) 98 (96–98) 98 (97–98) 98 (96–98) 0.970†
*Comparison of men and women.
†Mann–Whitney U test.
‡χ2 test.
§This is based on the 67 participant subsample with obstructive spirometry.
¶Kruskal–Wallis test.
**Fisher’s exact test.
LLN, lower limit of normal; PEF, peak expiratory flow; ULN, upper limit of normal.
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dispels misconceptions that they cannot perform spirometry
successfully.
The participants are long-lived, and survivors of some of the
most remarkable historical periods of our time, starting in the
year of their birth immediately post World War I and the 1918
Spanish influenza pandemic. There were high levels of depriv-
ation, and unemployment across Britain reached 17% in 1921.
This period was pre welfare state, Housing Act (1930), Clean
Air Act and widespread use of penicillin (1940). Many of the
participants would have been nearing retirement age when the
1986 WHO: Ottawa Charter for Health Promotion was intro-
duced—smoking rates are particularly high for men.
It is therefore not unexpected that a high prevalence of
physician-diagnosed COPD (16.7%) was identified compared
with previous self-reports of COPD of 10% in 65–74 year olds
in the 2010 Health Survey for England.17 Nevertheless there
were signs of potential misdiagnosis of COPD with a significant
proportion of those with physician-diagnosed COPD having no
evidence of airflow obstruction on spirometry, no smoking or
occupational history and minimal symptoms. At the same time,
a high proportion of our HRG fulfilled spirometry criteria for
COPD using current GOLD/NICE guidelines, though use of
LLN and GLI criteria rather than GOLD or NICE guidelines
might reduce levels of misdiagnosis.
The risk of respiratory impairment increases with age due to
the cumulative lifetime effect of environmental insults from
active and passive cigarette smoking, air pollution, occupational
dusts and infections.18 19 When this risk is added to the changes
which occur in the respiratory system as part of normal ageing,
including reduced ventilatory control, reduced respiratory
muscle strength, increased compliance and less favourable
respiratory mechanics due to reduced movement of the chest
wall,7 it is not surprising that symptoms of cough, wheeze and
dyspnoea are common in older people. All of these factors are
likely to reduce measured lung function, which has been shown
to be an independent risk factor for frailty and death.20–22
Distinguishing physiological age-related loss of lung function
from a pathological disease process in the lungs is further com-
plicated by a reduced perception of respiratory symptoms that
occurs with increasing age as demonstrated by significantly
reduced awareness of measured bronchospasm after a methacho-
line challenge in older compared with younger patients.23
Despite the high prevalence of chronic lung disease and respira-
tory symptoms, we found a significant proportion, 50% of men
and 40% of women, with no reported limitations due to breath-
lessness suggesting many are either able to function very well or
have a poor perception of symptoms.
The strengths of this work are the comprehensive assessment
of respiratory health and lung disease in a large population-
based cohort of 85 year olds, including those in institutional
care and those with cognitive impairment, in a stable urban
setting and with little ethnic diversity. The cohort of >800 par-
ticipants was achieved through engagement with 83% of the
general practices in the area and a consent rate of almost 60%
in those approached to participate. Previous studies of respira-
tory health in older subjects have relied on self-reported diag-
noses whereas in our study the use of general practice records
significantly improves the validity of our findings.24 25
Furthermore by conducting spirometry in the participant’s
place of residence using trained research nurses we were able to
achieve a very high uptake of this assessment, in contrast to the
known selection bias if participants had been required to attend
a clinic for assessment. Although participants opting in for the
health assessment were not a random sample of those eligible,
there was little evidence to suggest they had more or less
respiratory disease than those refusing the health assessment. In
Figure 4 Distribution curves of FEV1 and FVC of participants in the healthy reference group (all, men and women) measured (blue) and predicted
(green).
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addition they were sociodemographically representative of their
England and Wales birth cohort.4 A potential limitation of the
study is that those who agreed to participate may be healthier
and less frail than those who declined to participate and those
with cognitive impairment may have been under-represented.
Although some information was collected about why those
invited declined to participate, we obviously do not have
objective data on their respiratory health or disease burden.
However the prevalence of COPD of 16.7% in those who
agreed to MDHA and GPRR (n=845) was very similar to the
prevalence of 16.5% reported previously in all participants
with GPRR data (n=1030),4 suggesting that in terms of COPD,
those agreeing to MDHA had similar respiratory health profiles
to the larger study population. While 85 year olds in this urban
area in North-East England are sociodemographically and eth-
nically similar to the same birth cohort in England and Wales
as a whole, they may differ from those in other parts of the
world.
This study has revealed a substantial burden of respiratory
symptoms and respiratory disease, particularly COPD, in a
cohort of the very old aged 85 years; a group with substantial
environmental exposures recorded through smoking and occu-
pational exposure, which are known risk factors for lung
disease. Despite these observations, we show a good proportion
of participants functioning well with no respiratory symptoms
or diagnoses. Lung function tests revealed only 75.6% of the
COPD group satisfied spirometry criteria whereas 44% of the
healthy group satisfied spirometry criteria for COPD using
GOLD criteria. Healthcare professionals need to recognise that
spirometry can be reliably assessed in the vast majority of this
age group but care is needed as to how this is interpreted.
Current definitions of COPD based on spirometry may lead to
overdiagnosis in a group with transient symptoms and ‘normal’
lung ageing, whereas at the same time failure to use spirometry
to assess symptoms in this age group may lead to mislabelling
those with breathlessness or cough as having COPD when there
are other explanations.
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